Patent Royalties & Pharma Profit Over Lifesaving Care

January 10, 2023

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf

Patent royalties and pharmaceutical profits over lifesaving care?

Carl Tuttle

Hudson, NH, United States
Dr. Raymon Dattwyler 

JAN 8, 2023 — 

Please see the following letter addressed to Dr. Raymond Dattwyler who owns 24 patents for Lyme disease that include diagnostic testing and vaccines both live bacteria and oral.

Gomes-Solecki co-owns 17 patents with Dattwyler.

To view these patents, go to…

Patent Public Search Basic
https://ppubs.uspto.gov/pubwebapp/static/pages/ppubsbasic.html

———- Original Message ———-

From: CARL TUTTLE <runagain@comcast.net>
To: “Raymond_Dattwyler@nymc.edu” <Raymond_Dattwyler@nymc.edu>
Cc: “npjvaccines@nature.com” <npjvaccines@nature.com>, “abarrett@utmb.edu” <abarrett@utmb.edu>, “R.W.Titball@exeter.ac.uk” <R.W.Titball@exeter.ac.uk>, “mgomesso@uthsc.edu” <mgomesso@uthsc.edu>
Date: 01/06/2023 2:46 PM
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease

npj Vaccines Jan 2022

The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5

Raymond J. Dattwyler & Maria Gomes-Solecki

Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author

Dear Dr. Dattwyler,

I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.

For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:

European Neurology 1995

Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104

Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d

Abstract

We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.

____________________________________________

In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:

Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0

So that brings me to the reason for this email…

Question:

Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades?  In other words, patent royalties and pharmaceutical profits over lifesaving care?

A response to this inquiry is requested.

Carl Tuttle
Hudson, NH

Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor

Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1

________________

**Comment**

We can thank Tuttle for doggedly pursuing fraud and corruption that is truly shackling thousands of sick patients to an obsolete model that is neither scientific nor logical.

BTW: the corruption continues:

Category:

Activism, Lyme, Testing, vaccines

Comments Off on Patent Royalties & Pharma Profit Over Lifesaving Care

%d bloggers like this: